Medication use and falls: Applying Beers criteria to medication review in Parkinson’s disease

Eleanor Yusupov\(^1\), Davina Chen\(^2\) and Bhuma Krishnamachari\(^1\)

Abstract

Objectives: Our goal was to assess the association between potentially inappropriate medication use and risk of falls in the Parkinson’s disease population.

Methods: This was a retrospective cohort study conducted at an outpatient Parkinson’s Disease Treatment Center. Individuals 65 years of age or older, diagnosed with Parkinson’s disease who attended at least three visits in 2015 for physical, occupational therapy, or physician’s visits were included in the study. Electronic medical records were utilized to perform chart reviews, and medications were analyzed to identify prescription medications, combination preparations, over-the-counter medications, and dietary supplements. The goal of this study was to test the following hypothesis: elderly individuals with Parkinson’s disease who take multiple potentially inappropriate medications are more likely to experience a fall compared to elderly individuals with Parkinson’s disease who do not take multiple potentially inappropriate medications.

Results: A higher mean number of prescription medications were associated with falls in elderly Parkinson’s disease patients (6.53 vs 5.21, \(p < 0.01\)). Polypharmacy (taking five or more prescription and nonprescription medications) was not significantly associated with falls. Patients taking potentially inappropriate medications specifically contraindicated for those with a history of falls and fractures were more likely to report falls (\(p < 0.04\)). Analysis of the specific therapeutic medication categories demonstrated no significant differences between those who did and did not report falls.

Conclusion: A future prospective study at Parkinson’s disease center should include an electronic medical record–based intervention to reduce the total number of medications, as well as to minimize the use of high-risk medications.

Keywords
Pharmacoepidemiology, drug safety, Beers criteria, Parkinson’s disease

Date received: 26 July 2017; accepted: 29 October 2017

Introduction

Parkinson’s disease (PD) is a neurodegenerative movement disorder that typically presents with tremor, rigidity, bradykinesia, and impaired balance.\(^1\) The prevalence of PD continues to rise with aging population.\(^2\) An association between drugs and falls in the elderly has long been studied.\(^3\) In part due to aging, and in part due to the symptoms of the disease, individuals with PD are at an increased risk of falls, with annual fall rates ranging from 46% to 68% in some PD populations which puts them at a significantly higher risk of suffering from fall-related injuries than the general population.\(^8\) Thus, falls negatively impact mobility and activities of daily living in PD patients, affecting their quality of life.\(^9\)

The American Geriatrics Society Beers Criteria recently updated criteria for potentially inappropriate medications (PIMs) that have unfavorable balance between adverse events and benefits linked to poor patient outcomes including falls.\(^10\) Almost 30% of adults over 65 years of age regularly use five or more prescription medications.\(^11\) Polypharmacy, defined by the World Health Organization as the “use of too many medicines per patient,”\(^12\) has been associated with adverse drug

\(^1\)Department of Clinical Specialties, New York Institute of Technology College of Osteopathic Medicine (NYIT COM), Old Westbury, NY, USA
\(^2\)New York Institute of Technology College of Osteopathic Medicine (NYIT COM), Old Westbury, NY, USA

Corresponding author:
Eleanor Yusupov, Department of Clinical Specialties, New York Institute of Technology College of Osteopathic Medicine (NYIT COM), Hannah and Charles Serota Academic Center, Room 139, Northern Blvd, PO 8000, Old Westbury, NY 11568-8000, USA.
Email: eyusupov@nyit.edu

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
events, hospitalization, mortality, and falls; however findings are mixed, and there is a lack of heterogeneity between studies. Additionally, there is a lack of consensus in the literature regarding the definition of polypharmacy.6,7,14

Multiple research studies have focused on the etiologies and consequences of falls in individuals with PD; however, the association of the use of multiple PIMs and falls in PD has not been studied, to our knowledge. The purpose of this retrospective study was to test the following hypothesis: elderly individuals with PD who take multiple PIMs are more likely to experience a fall compared to elderly individuals with PD who do not take multiple PIMs.

Methods

This retrospective cohort study was conducted at the Adele Smithers Parkinson’s Disease Treatment Center of the New York Institute of Technology’s (NYIT) College of Osteopathic Medicine (Old Westbury, NY). Depending on the needs of the patients, weekly sessions include one-on-one visits with occupational, speech, physical therapist, psychologist, and/or physician specializing in osteopathic manipulative medicine. Medication lists are updated at each office visit by a physical therapist and/or physician. This study was approved by the institutional review board of the NYIT on 3 May 2016, and the waiver of the informed consent was granted.

PD individuals aged 65 years and older of both genders were included in the study. Exclusion criteria were long-term therapy for addiction, less than three office visits and patients younger than 65 years of age. Since there is no prior literature on the incidence of falls in those individuals with Parkinson’s disease who do not take medications, sample size was calculated for multiple regression using a range of potential effect sizes. With a small effect size of 0.2, assuming alpha = 0.05, a power of 80%, the following minimum sample size would be needed: 51. With a medium effect size of 0.5, assuming alpha = 0.05, a power of 80%, the following minimum sample size would be needed: 23. With a large effect size of 0.8, assuming alpha = 0.05, a power of 80%, the following minimum sample size would be needed: 16. We aimed to collect at least 100 subjects.

Of the 199 individuals screened, 41 were excluded due to age or fewer than three office visits. Patients with less than three office visits were excluded from the study due to lack of continuity of care and incomplete medical records.

We analyzed data from electronic medical records (EMRs) of 158 individuals with PD, 65 years of age or older who attended at least three visits in 2015 for physical, occupational therapy or physician’s visits. All subjects were diagnosed with PD (ICD G20) by a licensed neurologist based on distinguishing clinical features and diagnostic criteria.15

Data were collected on quantity of medications, pharmacologic or therapeutic categories and net of sociodemographic controls, including age, gender, and race/ethnicity. A chart review was performed, and medications were analyzed to identify prescription medications, combination preparations, over-the-counter medications, and dietary supplements. The total number of prescribed medications was calculated by subtracting dietary supplements and over-the-counter medications from the total list of medications reported.

Polypharmacy was defined as the regular use of five or more prescription medications.14 Medication lists were cross-referenced with PIMs from the AGS 2015 Beers List, as well as the PIMs contraindicated in specific populations including PD and those with a history of falls and fractures.10 Data were also analyzed using a definition or six or more or seven or more medications as the cutoff for polypharmacy, to ensure that the definition did not affect our results.

History of a diagnosis was reported for PD, balance disorders, depression and anxiety disorders, diabetes, chronic pain, dementia, hypertension, arthritis, osteoporosis, and vision problems. Fall-related history included number of falls during study period, injuries associated with falls, hospitalizations from falls, alcohol use, fear of falling, freezing, reported loss of balance, and use of a walking aid. The Centers for Disease Control and Prevention (CDC) defines a fall when “a person unintentionally comes to rest on the ground or another lower level, with or without loss of consciousness.”16 Freezing (difficulty initiating gait) is an important motor symptom of PD that plays a role in increasing fall risk in these patients.8

Differences between comparison groups were tested using a chi-square or Fisher’s exact statistic for categorical variables and a t-test for continuous variables. For multivariable analysis of categorical outcome variables, unconditional logistic regression was used to estimate odds ratios and 95% confidence intervals, adjusted for any covariates for which there was a significant difference in results between the two comparison groups. As demographic variables were not significantly different between groups, they were not adjusted for. Freezing, an independent risk factor for falls, was distributed differently between groups, and thus, logistic regression was performed adjusting for this variable.

Results

Table 1 shows the demographic characteristics of the study population. Of those enrolled, 81 participants (51%) reported ≥1 fall and 77 (49%) reported no falls. The mean age, gender breakdown, and racial breakdown were not significantly different between those who reported falls and those that did not report falls. There was a statistically significant difference between the two groups in reported incidences of freezing. Of those who reported falls, 55.56% (n=45) reported freezing, while 24.68% (n=19) of those who did not report falls, reported freezing (p<0.0001).
Table 1. Demographics of the study population.

| Characteristic          | Falls (N=81) | No falls (N=77) | p-value |
|-------------------------|-------------|-----------------|---------|
|                         | Mean (SD)   | Mean (SD)       |         |
| Age                     | 75.37 (6.59)| 75.19 (7.25)    | 0.87    |
|                         | N (%)       | N (%)           |         |
| Gender                  |             |                 | 0.80    |
| Female                  | 30 (37.04)  | 30 (38.96)      |         |
| Male                    | 51 (62.96)  | 47 (61.04)      |         |
| Ethnicity               |             |                 | 0.07    |
| Caucasian               | 53 (68.83)  | 67 (83.75)      |         |
| African American        | 2 (2.60)    | 0 (0)           |         |
| Hispanic                | 5 (6.49)    | 1 (1.25)        |         |
| Asian                   | 4 (5.19)    | 1 (1.25)        |         |
| Hebrew/Jewish           | 2 (2.60)    | 0 (0)           |         |
| Chose not to report     | 11 (14.29)  | 11 (13.75)      |         |
| Years since diagnosis   | 8.89 (7.44) | 7.21 (8.59)     | 0.19    |
| Average number of falls | 3.40 (5.57) | 0 (0)           |         |
| Freezing                | 45 (55.56)  | 19 (24.68)      | <0.0001 |

SD: standard deviation.

Table 2. Study population stratified by comorbidities.

| Comorbidities          | Falls (N=81) | No falls (N=77) | p-value |
|------------------------|-------------|-----------------|---------|
|                        | N (%)       | N (%)           |         |
| Depression/anxiety     | 29 (35.80)  | 13 (17.11)      | 0.01    |
| Diabetes               | 8 (10.00)   | 6 (7.89)        | 0.65    |
| Hypertension           | 24 (30.00)  | 19 (25.00)      | 0.48    |
| Arthritis              | 12 (15.38)  | 17 (22.37)      | 0.27    |
| Osteoporosis           | 2 (2.56)    | 2 (2.63)        | 0.98    |
| Vision impairment      | 9 (11.39)   | 7 (9.09)        | 0.64    |

Table 2 shows the breakdown of comorbidities in the study population. The percentage of history/presence of depression or anxiety in those also reported falls was 35.8% (n=29) and 17.11% (n=13) in those not reporting falls. There was a statistically significant difference in depression and anxiety between the two groups (p=0.01). There was no significant difference in other comorbidities including diabetes, hypertension, arthritis, osteoporosis, and vision problems between fallers and nonfallers.

Table 3 shows the mean number of medications used by those who did and did not report falls. The mean number of prescription medications taken by those who reported falls was 6.53 (standard deviation (SD)=3.31), while in those who did not report falls, the mean number was 5.21 (SD=2.63). The difference was statistically significant (p=0.01). The mean number of PIMs contraindicated in patients with history of falls taken by those who reported falls was 0.55 (SD=0.50), while in those who did not report falls, the mean number was 0.34 (SD=0.48). The difference was statistically significant (p=0.01). There were no differences between those who did and did not report falls in terms of total number of medications, number of over-the-counter medications, or number of PIMs.

Table 4 shows the use of specific categories of drugs used by those who did and did not report falls. There were no statistically significant differences seen between groups in terms of use of specific medication categories.

Table 5 shows the odds of medication use by those who did and did not report falls. Taking any medication, prescription medications, nonprescription medications, or PIMs was not significantly associated with falls. Taking PIMs contraindicated in patients with history of falls was associated with falls. The odds ratio comparing use of these medications in those who reported falls versus those who did not report falls was 2.32 (95% confidence interval (CI)=1.22–4.40, p=0.04).

Table 6 shows the odds of polypharmacy use by those who did and did not report falls. Polypharmacy including all prescription and nonprescription medications was not significantly associated with falls. When data were analyzed
using a medication cutoff or six or seven or more medications, no significant results were seen (data not shown).

**Discussion**

The practice of prescribing multiple medications to older patients is associated with adverse events in the literature, including the potential of drug–drug interactions and serious adverse effects of medications, including hospitalizations.\(^\text{17,18}\) In this study, we found that individuals taking PIMs specifically contraindicated for those with a history of falls and fractures, per Beers guidelines, were more likely to report falls.\(^\text{10}\) Analysis of the specific therapeutic medication categories demonstrated no significant differences between those who did and did not report falls.

Our findings are supported by those reported from the population-based prospective cohort study which demonstrated that fall risk is associated with daily use of multiple drugs only when at least one drug is an established fall-risk increasing drug.\(^\text{7}\) Others showed that the use of more than one prescribed medication can double the risk of falls leading to hospitalizations, even after adjusting for demographics, social circumstances, or comorbidities.\(^\text{19}\)

With regard to specific medication categories, previous studies reported mixed results. Schrag et al.\(^\text{20}\) found no association between the use of sleep medications and falls in PD, while others reported higher risk of falls in elderly individuals taking long-acting benzodiazepines and sedative hypnotics.\(^\text{3,21,22}\) The use of antidepressants (selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs)) and neuroleptics was previously reported to be associated with falls in PD patients.\(^\text{20}\) We did not find this association in our study.

It is noteworthy that of the 158 individuals observed, 104 were prescribed at least one PIM. Prevalence of PIMs (66%) in our sample of elderly individuals with PD is much higher than PIM prevalence of 22%–30% documented in studies of community-dwelling elderly populations.\(^\text{23,24}\) therefore

### Table 3. Medication use and falls.

|                              | Falls (N=81) | No falls (N=77) | p-value |
|------------------------------|-------------|----------------|---------|
| Total number of medications  | 7.99 (4.14) | 6.88 (3.68)    | 0.87    |
| Number of prescribed medications | 6.53 (3.31) | 5.21 (2.63)    | 0.01    |
| Number of over-the-counter medications | 1.46 (1.88) | 1.68 (1.95)    | 0.47    |
| Number of PIMs               | 1.30 (1.38) | 0.94 (1.06)    | 0.07    |
| Number of PIMs contraindicated due to history of falls | 0.55 (0.50) | 0.34 (0.48)    | 0.01    |

PIM: potentially inappropriate medication; SD: standard deviation.

### Table 4. Specific categories of medication use and falls.

| Therapeutic category or drug                          | Falls (N=81) | No falls (N=77) | p-value |
|-------------------------------------------------------|-------------|----------------|---------|
| Levodopa/carbidopa                                    | 65 (80.25)  | 57 (74.03)     | 0.35    |
| Amantadine                                            | 12 (14.81)  | 8 (10.39)      | 0.40    |
| Anticholinergics                                      | 4 (4.94)    | 4 (5.19)       | 1.0     |
| Monoamine oxidase B inhibitors                        | 39 (48.15)  | 28 (36.36)     | 0.13    |
| Dopamine agonants                                     | 20 (24.69)  | 12 (15.58)     | 0.15    |
| COMT inhibitors                                       | 6 (7.41)    | 2 (2.60)       | 0.28    |
| Other antiparkinson agents: benztrapine, trihexyphenidyl | 2 (2.47)    | 3 (3.90)       | 0.68    |
| Antipsychotics                                        | 5 (6.54)    | 5 (6.58)       | 0.93    |
| Antidepressants                                       | 20 (24.69)  | 16 (21.05)     | 0.53    |
| Anticonvulsants                                       | 9 (11.25)   | 3 (3.95)       | 0.14    |
| Benzodiazepines                                       | 20 (24.69)  | 10 (13.16)     | 0.07    |
| Cardiovascular drugs                                  | 5 (6.25)    | 5 (6.58)       | 0.93    |
| Gastrointestinal drugs                                | 16 (20)     | 9 (11.84)      | 0.17    |
| Narcotics/opioids                                     | 4 (5.06)    | 4 (5.26)       | 0.59    |
| Nonopiate analgesics                                  | 8 (10)      | 12 (15.79)     | 0.36    |
| Nonbenzodiazepine receptor agonist                    | 7 (8.75)    | 2 (2.63)       | 0.10    |

COMT: catechol-0-methyl transferase.
making it difficult to compare published studies on the elderly and falling with our own study.

We found that depression and anxiety in individuals with PD were associated with falls. Similar research findings in community-dwelling elderly population demonstrated that depressive symptoms increase the risk of falls, independent of the use of antidepressant medications. These findings and high prevalence of depression in PD population suggest a potential benefit of screening for depression in Parkinson’s patients in multifactorial fall prevention interventions. In our study, freezing was associated with falls, similar to what has been previously reported. No association between falls and arthritis, or other chronic diseases, such as diabetes, hypertension, osteoporosis, or vision problems, was found.

Among limitations of this study method is its retrospective design. However, reliability and validity of retrospective chart review for this type of study have been previously shown by others. Other potential limitations are the small size of sample and reliability of the collected data. It is possible that there was a lack of significant effect seen with these PIMs due to the small sample size. The data were also limited in that information on medication dosages was not gathered, and no information was available in the medical charts on severity of PD disease, and thus, these variables were not controlled for. Finally, data collected from EMRs on prescribed medications may be incomplete or missing.

A challenge to this study was defining the appropriateness of medications. Medications identified by the updated Beers criteria are “potentially inappropriate,” not “definitely inappropriate” due to complexities of pharmacotherapy in older patients with comorbidities. Clinicians caring for PD patients should use the 2015 AGS Beers criteria as a starting point for identification of potentially harmful medications and search for safer alternatives.

CDC has recognized a need to increase awareness among primary care physicians to conduct comprehensive medication review as part of the fall-risk assessment in the elderly. This medication review should include an evaluation of number of medications and screening for PIMs, eliminating of potential therapeutic duplications, and screening for drug–drug interactions.

Table 5. Odds ratios for medication use and falls.

| Medication use | Falls (N = 81) | No falls (N = 77) | Unadjusted OR (CI) | p-value | OR (95% CI) | p-value |
|---------------|---------------|------------------|--------------------|---------|-------------|---------|
| Takes any medications (prescription and over-the-counter medications) | 80 (98.77) | 76 (98.70) | 1.05 (0.07–17.13) | 0.97 | 1.22 (0.06–23.20) | 0.90 |
| Takes at least one prescription medication | 79 (97.53) | 75 (97.40) | 1.05 (0.15–7.67) | 0.96 | 0.85 (0.12–6.70) | 0.88 |
| Takes at least one over-the-counter medication | 46 (56.79) | 48 (62.34) | 0.79 (0.42–1.50) | 0.48 | 0.81 (0.41–1.58) | 0.30 |
| Takes at least one PIM | 57 (70.37) | 46 (59.74) | 1.60 (0.83–3.10) | 0.16 | 1.48 (0.74–3.00) | 0.27 |
| Takes at least one PIM contraindicated due to history of falls | 45 (55.56) | 27 (35.06) | 2.32 (1.22–4.40) | 0.01 | 2.07 (1.05–4.02) | 0.04 |

OR: odds ratio; CI: confidence interval; PIM: potentially inappropriate medication.
*Controlled for freezing.

Table 6. Odds ratios for polypharmacy and falls.

| Polypharmacy | Falls (N = 81) | No falls (N = 77) | Unadjusted OR (CI) | p-value | OR (95% CI) | p-value |
|---------------|---------------|------------------|--------------------|---------|-------------|---------|
| Polypharmacy—prescription and over-the-counter medications | 63 (77.78) | 56 (72.73) | 1.31 (0.64–2.71) | 0.46 | 1.13 (0.52–2.42) | 0.76 |
| Polypharmacy—prescription medications | 60 (74.07) | 48 (62.34) | 1.73 (0.88–3.40) | 0.11 | 1.53 (0.75–3.13) | 0.24 |
| Polypharmacy—over-the-counter medications | 8 (9.88) | 9 (11.69) | 0.83 (0.30–2.27) | 0.71 | 0.56 (0.18–1.60) | 0.26 |
| Polypharmacy—PIMs | 2 (2.47) | 1 (1.30) | 1.92 (0.17–21.66) | 0.60 | 0.84 (0.07–9.83) | 0.89 |

OR: odds ratio; CI: confidence interval; PIM: potentially inappropriate medication.
*Five or more medications.
*Adjusted for freezing.
A future prospective study at PD center should include an EMR-based intervention to reduce the total number of medications, as well as minimize the use of high-risk medications. EMR has been previously used to conduct a comprehensive medication review in vulnerable patient population6,36 and to alert the primary care physician of the changes that may help to prevent falls.6

Despite its limitations, the results of this study demonstrate that a higher mean number of prescription medications were associated with falls in elderly individuals with PD. This demonstrates the importance of conducting a comprehensive medication review as part of a multifactorial fall prevention program in PD.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval
Ethical approval for this study was obtained from New York Institute of Technology Institutional Review Board BHS-1197.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Informed consent
Informed consent requirement was waived by the IRB.

References
1. Burch D and Sheerin F. Parkinson’s disease. Lancet 2005; 365(9459): 622–627.
2. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007; 68(5): 384–386.
3. Berdot S, Bertrand M, Darigues JF, et al. Inappropriate medication use and risk of falls—a prospective study in a large community-dwelling elderly cohort. BMC Geriatr 2009; 9: 30.
4. Ferreri S, Roth MT, Casteel C, et al. Methodology of an ongoing, randomized controlled trial to prevent falls through enhanced pharmaceutical care. Am J Geriatr Pharm 2008; 6(2): 61–81.
5. Huang ES, Karter AJ, Danielson KK, et al. The association between the number of prescription medications and incident falls in a multi-ethnic population of adult type-2 diabetes patients: the diabetes and aging study. J Gen Intern Med 2010; 25(2): 141–146.
6. Weber V, White A and McIvried R. An electronic medical record (EMR)-based intervention to reduce polypharmacy and falls in an ambulatory rural elderly population. J Gen Intern Med 2008; 23(4): 399–404.
7. Ziere G, Dieleman JP, Hofman A, et al. Polypharmacy and falls in the middle age and elderly population. Brit J Clin Pharmac 2006; 61(2): 218–223.
8. Voss TS, Elm JJ, Wielinski CL, et al. Fall frequency and risk assessment in early Parkinson’s disease. Parkinsonism Relat D 2012; 18(7): 837–841.
9. Michalowska M, Fiszer U, Krygowska-Wajs A, et al. Falls in Parkinson’s disease: causes and impact on patients’ quality of life. Funct Neurol 2005; 20(4): 163–168.
10. American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2015; 63(11): 2227–2246.
11. Qato DM, Alexander GC, Conti RM, et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 2008; 300(24): 2867–2878.
12. World Health Organization. Promoting rational use of medicines: core components. Geneva: World Health Organization, 2002.
13. Fried TR, O’Leary J, Towle V, et al. Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review. J Am Geriatr Soc 2014; 62(12): 2261–2272.
14. Gnijdic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol 2012; 65(9): 989–995.
15. Suchowersky O, Reich S, Perlmutter J, et al. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66(7): 968–975.
16. Stevens JA, Corso PS, Finkelstein EA, et al. The costs of fatal and non-fatal falls among older adults. Injury Prevention 2006; 12(5): 290–295.
17. Marcum ZA, Amuan ME, Hanlon JT, et al. Prevalence of unplanned hospitalizations caused by adverse drug reactions in older veterans. J Am Geriatr Soc 2012; 60(1): 34–41.
18. Runganga M, Peel NM and Hubbard RE. Multiple medication use in older patients in post-acute transitional care: a prospective cohort study. Clin Interv Aging 2014; 9: 1453–1462.
19. Helgadóttir B, Laflamme L, Monárrez-Espino J, et al. Medication and fall injury in the elderly population; do individual demographics, health status and lifestyle matter? BMC Geriatr 2014; 14(1): 92.
20. Schrag A, Choudhury M, Kaski D, et al. Why do patients with Parkinson’s disease fall? A cross-sectional analysis of possible causes of falls. npj Parkinson’s Disease 2015; 1: 15011.
21. Ray WA, Thapa PB and Gideon P. Benzodiazepines and the risk of falls in nursing home residents. J Am Geriatr Soc 2000; 48(6): 682–685.
22. Stockl KM, Le L, Zhang S, et al. Clinical and economic outcomes associated with potentially inappropriate prescribing in the elderly. Am J Manag Care 2010; 16(1): e1–e10.
23. Reich O, Rosemann T, Rapold R, et al. Potentially inappropriate medication use in older patients in Swiss managed care plans: prevalence, determinants and association with hospitalization. PLoS ONE 2014; 9(8): e105425.
24. Zhan C, Sang J, Bierman AS, et al. Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 Medical Expenditure Panel Survey. JAMA 2001; 286(22): 2823–2829.
25. Byers AL, Sheeran T, Mlodzianowski AE, et al. Depression and risk for adverse falls in older home health care patients. Res Gerontol Nurs 2008; 1(4): 245–251.
26. Gale CR, Cooper C and Aihie Sayer A. Prevalence and risk factors for falls in older men and women: the English Longitudinal Study of Ageing. Age Ageing 2016; 45(6): 789–794.
27. King LA, Priest KC, Nutt J, et al. Comorbidity and functional mobility in persons with Parkinson disease. Arch Phys Med Rehab 2014; 95(11): 2152–2157.
28. Ashburn A, Stack E, Ballinger C, et al. The circumstances of falls among people with Parkinson’s disease and the use of Falls Diaries to facilitate reporting. Disabil Rehabil 2008; 30(16): 1205–1212.
29. Askari M, Eslami S, Scheffer AC, et al. Different risk-increasing drugs in recurrent versus single fallers: are recurrent fallers a distinct population? Drug Aging 2013; 30(10): 845–851.
30. Chiu MH, Lee HD, Hwang HF, et al. Medication use and fall-risk assessment for falls in an acute care hospital. Geriatr Gerontol Int 2015; 15(7): 856–863.
31. Freeland KN, Thompson AN, Zhao Y, et al. Medication use and associated risk of falling in a geriatric outpatient population. Ann Pharmacother 2012; 46(9): 1188–1192.
32. McMahon CG, Cahir CA, Kenny RA, et al. Inappropriate prescribing in older fallers presenting to an Irish emergency department. Age Ageing 2014; 43(1): 44–50.
33. Steinman MA, Beizer JL, DuBeau CE, et al. How to use the American Geriatrics Society 2015 Beers Criteria—a guide for patients, clinicians, health systems, and payors. J Am Geriatr Soc 2015; 63(12): e1–e7.
34. Smith ML, Stevens JA, Ehrenreich H, et al. Healthcare providers’ perceptions and self-reported fall prevention practices: findings from a large New York health system. Front Public Health 2015; 3: 17.
35. Kaniewski M, Stevens JA, Parker EM, et al. An introduction to the Centers for Disease Control and Prevention’s efforts to prevent older adult falls. Front Public Health 2014; 2: 119.
36. Zechmann S, Senn O, Valeri F, et al. The impact of an individualized risk-adjusted approach on hypertension treatment in primary care. J Clin Hypertens 2017; 19: 510–518.